Mass General Brigham Researchers Find Too Much Sitting Hurts the Heart
New study shows that being sedentary increases the risk of the most common types of heart disease, even among those who get enough exercise
Press Release5 Minute ReadApr | 4 | 2022
Saumya Das, MD, PhDThe past decade has seen investigators discover new functions of RNAs that do not translate into proteins.
BOSTON – The body’s ability to respond to various types of stress is essential for maintaining health, and failure of such adaptive stress responses can trigger or worsen numerous diseases. New research led by investigators at Massachusetts General Hospital (MGH) and published in Advanced Science reveals that cells often release certain RNA molecules called tDRs in response to stressors, and that different tDRs may serve as markers of cellular stress in different diseases.
“RNA molecules have long been known to be the messenger between DNA (the genetic code) and proteins (the functional molecules of the cell); however, the past decade has seen investigators discover new functions of RNAs that do not translate into proteins—the so-called non-coding RNAs,” says senior author Saumya Das, MD, PhD, co-director of the Resynchronization and Advanced Cardiac Therapeutics Program at MGH.
Das notes that there’s a growing list of non-coding RNAs with diverse functions, and among these, a new class of RNAs has been found to arise from so-called transfer RNAs that normally function to help make proteins from classic messenger RNAs. These RNAs, called tRNA-derived small RNAs (tDRs), appear to be generated when larger “parent” tRNAs are cut into smaller versions by stress-activated enzymes.
By studying a variety of human and rat cells under three stressors—nutritional deprivation, low oxygen and oxidative stress—that are often present in many disease states, Das and his colleagues generated a comprehensive landscape of tDRs that can be found inside cells (cellular) and outside cells (extracellular) during different stress responses. They also found that key proteins called RNAses are important for the generation and stability of extracellular tDRs.
“While tDRs play important roles in cellular functions, we have also found that tDRs are released by cells where they may serve as markers of cellular stress in different diseases,” says lead author Guoping Li, PhD, an instructor in medicine at MGH and Harvard Medical School. “We saw that different types of stress signals can affect the cellular and extracellular tDRs in different types of cells, and that there are ‘signatures’ of these stress signals.”
The team created an atlas of the stress signatures for both cellular and extracellular tDRs that can be used not only as indicators of disease but also as a starting point for scientists who are interested in studying the roles of distinct tDRs in cancer, fibrosis, and other conditions. Das and colleagues are focusing on one such tDR and its role in kidney disease.
The study’s co-authors include Guoping Li, Aidan C. Manning, Alex Bagi, Xinyu Yang, Priyanka Gokulnath, Michail Spanos, Jonathan Howard, Patricia P. Chan, Thadryan Sweeney, Robert Kitchen, Haobo Li, Brice D. Laurent, Sary F. Aranki, Maria I. Kontaridis, Louise C. Laurent, Kendall Van Keuren-Jensen, Jochen Muehlschlegel, and Todd. M. Lowe.
This work was supported by the American Heart Association and the National Institutes of Health.
About the Massachusetts General Hospital
Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The Mass General Research Institute conducts the largest hospital-based research program in the nation, with annual research operations of more than $1 billion and comprises more than 9,500 researchers working across more than 30 institutes, centers and departments. In August 2021, Mass General was named #5 in the U.S. News & World Report list of "America’s Best Hospitals." MGH is a founding member of the Mass General Brigham health care system.
New study shows that being sedentary increases the risk of the most common types of heart disease, even among those who get enough exercise
An international, phase 3 clinical trial led by investigators at Mass General Brigham could improve the treatment of a rare disease that can cause debilitating symptoms.
The 2024 class of awardees will receive more than $6 million in funding to accelerate groundbreaking cancer research.
Mass General Brigham researchers found that getting vaccinated on the early side of the recommended window was best for transferring maternal antibodies to the fetus.
The researchers found that damage to the heart is driven by a different immune response than the anti-tumor one, suggesting that this serious complication could one day be managed without halting cancer therapy.
The John and Ashley Ranelli Endowed Scholar in Cancer Innovation will activate funding of promising cancer research, helping to advance critical work in the fight against cancer.